2024-02-15 08:19:45 ET
Summary
- ClearPoint Neuro's stock has performed well over the past 4 months, supported by solid business fundamentals.
- Despite the move higher, ClearPoint's valuation is still modest, given the company's potential.
- The progression of therapies through clinical trials, along with the rollout of its laser therapy system and operating room system, should drive solid growth in 2024.
ClearPoint Neuro's (CLPT) stock has performed well over the past 4 months, with business fundamentals remaining solid. The stock is still down YoY though and ClearPoint's valuation is still modest given the company's potential. The full rollout of its laser therapy and the introduction of its systems into operating rooms should help drive growth in 2024. In addition, partners continue to progress therapies through clinical trials, both solidifying ClearPoint's competitive position and increasing the probability of larger revenue streams in the future.
Market
ClearPoint Neuro uses intra-procedural magnetic resonance imaging to guide minimally invasive procedures, including surgery (stimulation, ablation and biopsy) and the delivery of therapeutics. Minimally invasive surgery is generally preferred for a variety of reasons, but for some procedures it is unavailable or extremely complex, something that intra-procedural MRI can help with....
Read the full article on Seeking Alpha
For further details see:
ClearPoint Neuro: Potential Inflection Point